ES2573682T3 - Agentes de interrupción vascular activados por MMP - Google Patents

Agentes de interrupción vascular activados por MMP Download PDF

Info

Publication number
ES2573682T3
ES2573682T3 ES12160556.2T ES12160556T ES2573682T3 ES 2573682 T3 ES2573682 T3 ES 2573682T3 ES 12160556 T ES12160556 T ES 12160556T ES 2573682 T3 ES2573682 T3 ES 2573682T3
Authority
ES
Spain
Prior art keywords
mmp
vascular
resin
agents activated
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12160556.2T
Other languages
English (en)
Inventor
Jason Gill
Paul Loadman
Robert Falconer
Laurence Patterson
Jennifer Atkinson
Michael Bibby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incanthera Ltd
Original Assignee
Incanthera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incanthera Ltd filed Critical Incanthera Ltd
Application granted granted Critical
Publication of ES2573682T3 publication Critical patent/ES2573682T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto, o sal farmacéuticamente aceptable del mismo, que comprende un agente de interrupción vascular (VDA) que es un agente anticancerígeno ligado a un péptido que comprende un sitio de división proteolítica de matriz de metaloproteinasa (MMP) que comprende la secuencia de aminoácidos -Arg-Ser-Cit-Gly-Hof-Tyr-Leu-.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
5
10
15
20
25
30
35
40
δH (600 MHz, CDCl3), 10.08 (1 H, amplio s, NH), 8.99 (1 H, d J 10.7, C11-H), 7.71 (2 H, d, J 6.2, C23-H, C24-H),
7.55 (1 H, s, C8-H), 7.49 (2 H, dd, J 6.5 y 6.5, C20-H, C27-H), 7.41 (1 H, d, J 10.2, C10-H), 7.33 (2 H, dd, J 6.2 y 6.2, C22-H, C25-H), 7.26-7.21 (2 H, m, C21-H, C26-H), 6.91 (2 H, d, J 8.3, C14-H, C17-H), 6.56 (2 H, d, J 7.2, C15-H, C16-H), 6.45 (1 H, s, C4-H), 5.93 (1 H, amplio s, NH), 5.28 (1 H, s, NH), 4.95-4.90‘ (1 H, m, C12-H), 4.60 (1 H, ddd, J 11.7, 5.8 y 6.9, C7-H), 4.39 (1 H, dd, J 8.9 y 8.6, C18-CH2), 4.29-4.24 (1 H, m, C18-CH2), 4.12 (1 H, dd, J 6.9 y 6.9, C19-H), 3.90 (3 H, s, OCH3), 3.84 (3 H, s, OCH3), 3.54 (3 H, s, OCH3), 3.08 (2 H, d, J 5.2, C13-CH2), 2.44 (1 H, dd, J
13.4 y 6.2, C5-CH2), 2.33-2.26 (1 H, m, C5-CH2), 2.15-2.09 (1 H, m, C6-CH2), 1.82 (3 H, s, CH3), 1.75-1.69 (1 H, m, C6-CH2); ES m/z (%) 770 [M+] (100).
Preparación de 4:
Resina de cloruro de 2-Clorotritilo (Novabiochem, malla 100-200 m, sustitución 1.4 mmolg-1, 589 mg, 0.765 mmol,
1.00 eq) se suspende en una solución de 3 (589 mg, 0.765 mmol, 1.00 eq), dimetilaminopiridina (10 mg, 76.5 µmol,
0.01 eq), DiPEA (247 mg, 1.913 mmol, 333 µL, 2.50 eq) y piridina (241 mg, 3.061 mmol, 248 µL, 4.00 eq) en THF (10 mL) y se agita durante 6 horas a 50° C. La resina posteriormente se filtra y se lava profundamente con THF. La resina luego se finaliza al lavar la resina cuidadosamente con metanol (CH2Cl2:MeOH:DiPEA 17:2:1, 100 mL). La resina 4 se seca durante la noche sobre P2O5. Peso de resina seca: 593 mg (carga 56%).
Procedimiento general para síntesis de profármacos activados con endopeptidasa
imagen10
5 fluo-bala-glu-pro-cit-gly-hof-tyr-leu-tyr-colch
Como un ejemplo, el conjugado de péptido 5 se sintetiza utilizando síntesis de péptido en fase sólida convencional, a partir de derivado de colchicina inmovilizado 4, utilizando una estrategia con base en Fmoc.
Se logran ácidos de síntesis de péptido de estrategia Nα-Fmoc manualmente utilizando resina derivada de 2clorotritilo 4. La resina se hincha profundamente en DMF, seguido por eliminación del grupo protector N-Fmoc mediante tratamiento con 20% v/v de piperidina en DMF (3 x 3 min). Todos los acoplamientos se realizan en DMF, empleando 2.5 veces de exceso molar de aminoácidos protegidos de Nα-Fmoc (con grupos de protección de cadena lateral apropiados), y activados utilizando HCTU/HOBt/DiPEA. Se realizan desprotecciones de Nα-Fmoc utilizando 20% de piperidina en DMF (3 x 3 min). El éxito de acoplamientos y desprotecciones se monitoriza utilizando la prueba de Kaiser con basr rn ninhidrina. Se repiten los acoplamientos no exitosos. Después de la desprotección de Nα-Fmoc final, la cadena de péptido se finaliza con isotiocianato de fluoresceína (2.50 eq, en la presencia de DiPEA,
1.50 eq). El éxito de esta reacción también se monitoriza por la prueba de Kaiser.
Un residuo de β-alanina adicional se incorpora en la secuencia para superar la incompatibilidad del enlace de tiourea y las condiciones ácidas de la división (la tiourea se puede reorganizar, y el carbono carbonilo del enlace amida anterior se puede someter a ataque nucleófilo por la función similar sulfhihidrilo así formada. Esto conduce a la división del enlace amida, con la formación concomitante de una tiazolinona cíclica. LA tiazolinona se puede someter a redisposición en presencia de ácido acuoso para formar una tiohidantoína).
Sobre la terminación de la secuencia, la resina se lava (DMF, CH2Cl2, CH2Cl2/MeOH) y se seca en vacío sobre KOH a peso constante. Los péptidos se dividen a partir de la resina mediante acidolisis leve utilizando TFA-H2O triisopropilsilano 95:2.5:2.5 durante 2 h a temperatura ambiente, con desprotección de cadena lateral simultánea. Luego de división, el TFA se elimina bajo presión reducida. El producto crudo se extrae en 95% ácido acético acuoso y se liofiliza. El péptido crudo se analiza posteriormente utilizando HPLC de fase inversa y se purifica utilizando HPLC preparativo (pureza >97%). Las fracciones puras se combinan y se liofilizan. Se confirma la identidad mediante espectrometría de masas.
Adhesión potencial de la colchicina progenitora a una secuencia de péptidos es a través del anillo B
11
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES12160556.2T 2007-04-12 2008-03-27 Agentes de interrupción vascular activados por MMP Active ES2573682T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707034 2007-04-12
GBGB0707034.5A GB0707034D0 (en) 2007-04-12 2007-04-12 Compounds

Publications (1)

Publication Number Publication Date
ES2573682T3 true ES2573682T3 (es) 2016-06-09

Family

ID=38116587

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08718877.7T Active ES2573228T3 (es) 2007-04-12 2008-03-27 Agentes disruptores vasculares activados por MMP
ES12160565.3T Active ES2683168T3 (es) 2007-04-12 2008-03-27 Secuencia de escisión específica de MMP-14
ES12160556.2T Active ES2573682T3 (es) 2007-04-12 2008-03-27 Agentes de interrupción vascular activados por MMP

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES08718877.7T Active ES2573228T3 (es) 2007-04-12 2008-03-27 Agentes disruptores vasculares activados por MMP
ES12160565.3T Active ES2683168T3 (es) 2007-04-12 2008-03-27 Secuencia de escisión específica de MMP-14

Country Status (16)

Country Link
US (4) US8691751B2 (es)
EP (4) EP3348282A1 (es)
JP (4) JP5537413B2 (es)
CY (1) CY1120368T1 (es)
DK (3) DK2481429T3 (es)
ES (3) ES2573228T3 (es)
GB (1) GB0707034D0 (es)
HK (2) HK1174534A1 (es)
HR (1) HRP20181043T1 (es)
HU (3) HUE029080T2 (es)
LT (1) LT2481429T (es)
PL (3) PL2481429T3 (es)
PT (1) PT2481429T (es)
SI (1) SI2481429T1 (es)
TR (1) TR201807811T4 (es)
WO (1) WO2008125800A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) * 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) * 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9169337B2 (en) 2014-03-12 2015-10-27 Chevron Phillips Chemical Company Lp Polymers with improved ESCR for blow molding applications
GB2545169B (en) * 2015-12-01 2019-10-09 Ellipses Pharma Ltd Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
JP7360169B2 (ja) 2017-07-07 2023-10-12 カトリック ユニヴェルシテット ルーヴェン 無血管性または乏血管性微小腫瘍の治療

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263473A2 (en) * 2000-03-15 2002-12-11 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
GB0018240D0 (en) * 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
GB0105929D0 (en) * 2001-03-09 2001-04-25 Btg Int Ltd Physiologically activated prodrugs
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
ES2565543T3 (es) 2005-01-24 2016-04-05 Board Of Regents, The University Of Texas System Construcciones de fusión a Fc de unión a fosfatidilserina y su uso terapéutico
US20090022782A1 (en) 2005-02-25 2009-01-22 National University Corp. Hokkaido University Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic

Also Published As

Publication number Publication date
US9358303B2 (en) 2016-06-07
EP2134372B1 (en) 2016-02-24
US9956296B2 (en) 2018-05-01
SI2481429T1 (en) 2018-08-31
US20160243252A1 (en) 2016-08-25
JP6170590B2 (ja) 2017-07-26
WO2008125800A2 (en) 2008-10-23
PL2481429T3 (pl) 2018-10-31
DK2481429T3 (en) 2018-07-30
EP2481429A2 (en) 2012-08-01
GB0707034D0 (en) 2007-05-23
JP5931952B2 (ja) 2016-06-08
EP2481428A2 (en) 2012-08-01
PL2481428T3 (pl) 2016-09-30
PT2481429T (pt) 2018-06-19
JP2014196304A (ja) 2014-10-16
HUE027528T2 (en) 2016-10-28
US20180228910A1 (en) 2018-08-16
EP2134372A2 (en) 2009-12-23
HUE029080T2 (en) 2017-01-30
CY1120368T1 (el) 2019-07-10
ES2573228T3 (es) 2016-06-06
US20100168036A1 (en) 2010-07-01
HUE038633T2 (hu) 2018-11-28
JP2016190848A (ja) 2016-11-10
JP5911908B2 (ja) 2016-04-27
EP2481428A3 (en) 2013-07-24
TR201807811T4 (tr) 2018-06-21
US10556014B2 (en) 2020-02-11
JP2014193871A (ja) 2014-10-09
PL2134372T3 (pl) 2016-09-30
HK1258466A1 (zh) 2019-11-15
EP2481429B1 (en) 2018-05-09
JP2010523632A (ja) 2010-07-15
JP5537413B2 (ja) 2014-07-02
EP2481428B1 (en) 2016-03-02
DK2134372T3 (en) 2016-06-06
DK2481428T3 (en) 2016-06-13
HK1174534A1 (zh) 2013-06-14
HRP20181043T1 (hr) 2018-09-21
ES2683168T3 (es) 2018-09-25
WO2008125800A3 (en) 2008-12-04
LT2481429T (lt) 2018-09-10
EP3348282A1 (en) 2018-07-18
US20140179592A1 (en) 2014-06-26
EP2481429A3 (en) 2013-07-03
US8691751B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
ES2573682T3 (es) Agentes de interrupción vascular activados por MMP
JP6703668B2 (ja) ペプチド合成方法
CA3017926C (en) Methods for synthesizing .alpha.4.beta.7 peptide antagonists
Kawakami et al. Peptide thioester preparation based on an NS acyl shift reaction mediated by a thiol ligation auxiliary
RU2602042C2 (ru) Способ производства дегареликса и его промежуточных соединений
US9260480B2 (en) Process for the manufacture of Degarelix and its intermediates
KR20000036015A (ko) 알파-히드록시산 링커를 함유하는 펩티드 프로드럭
EP0830372A1 (en) Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
CA2399187C (en) Kahalalide compounds
ES2885869T3 (es) Procedimiento para la fabricación de degarelix y sus productos intermedios
JP6703669B2 (ja) リュープロレリンの製造方法
KR20110022594A (ko) 신규한 이중 표적화 항종양성 접합체
JPH09502434A (ja) キニノゲナーゼ阻害剤
US20030195152A1 (en) Polymeric conjugates of antitumor agents
EP2776471A1 (en) Stable peptide-based furin inhibitors
JP4615221B2 (ja) ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
CA2453245A1 (en) Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
WO1998012219A1 (en) Methionine, penicillamine and cysteine-analogue containing peptides having immunomodulating activity
HU230601B1 (hu) Eljárás Trp aminosavat tartalmazó peptid szintézisére
SK285387B6 (sk) Spôsob prípravy cyklo(Asp-DPhe-NMeVal-Arg-Gly)
US7999068B2 (en) Process for the preparation of bicyclic peptide compounds
AP546A (en) Peptides for inhibiting pepsin release.
CN109929007B (zh) 地加瑞克关键二肽中间体的制备方法
EP1348714B1 (en) Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use
KR20240004561A (ko) 포스포릴콜린 접합체를 포함하는 펩티드 및 이의 합성 방법